Cellectis
CLLS
$2.56
Share price
1.59%
Change (1 day)
31.28%
Change (1 year)
Categories
Operating Margin for Cellectis (CLLS)
Operating Margin as of May 2024 (TTM): -587.59%
According to Cellectis's latest financial reports and stock price the company's current Operating Margin is -587.59%. At the end of 2021 the company had an Operating Margin of -218.37%.
Operating Margin history for Cellectis from 2015 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -218.37% | 65.65% |
| 2020 | -131.82% | -82.62% |
| 2019 | -758.47% | 9.32% |
| 2018 | -693.83% | 68.55% |
| 2017 | -411.65% | 174.26% |
| 2016 | -150.10% | 270.93% |
| 2015 | -40.46% | -572.78% |
| 2014 | 8.56% | -102.41% |
| 2013 | -355.39% | 254.63% |
| 2012 | -100.21% | -17.36% |
| 2011 | -121.26% | 72.35% |
| 2010 | -70.36% | 3.98% |
| 2009 | -67.66% | 171.31% |
| 2008 | -24.94% | -85.33% |
| 2007 | -169.96% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 37.68% | -106.41% | 🇺🇸 USA |
 uniQure QURE | -120.45% | -79.50% | 🇳🇱 Netherlands |
 Novavax NVAX | -149.57% | -74.55% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | -79.07% | -86.54% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.